Navigation Links
Genetic testing not cost-effective in guiding initial dosing of common blood thinner
Date:1/19/2009

CINCINNATINew analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.

This study is being published in the Jan. 20, 2009, edition of Annals of Internal Medicine.

Warfarin is commonly prescribed to prevent blood clotting, particularly for patients with atrial fibrillationa type of abnormal heart rhythm.

Mark Eckman, MD, professor of medicine at UC and lead investigator of the study, says the U.S. Food and Drug Administration changed the labeling for warfarin in 2007, suggesting that clinicians consider genetic testing before initiating therapy.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," he says. "The idea behind genetic testingalso known as pharmacogenetic-guided dosing is to help guide the initial, and possibly lower, dose of warfarin for patients found to possess certain variants of the genes cytochrome P450 CYP2C9 and vitamin K epoxide reductase, or VKORC1. The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

Eckman says the study looked at whether the benefit of testing is worth the costs associated with it.

Researchers first performed an analysis combining the results of the only three clinical studies published to date to determine the degree to which pharmacogenetic-guided dosing decreases the risk of major bleeds when compared with standard induction of treatment with warfarin.

The team next constructed a model to estimate the cost-effectiveness of a genotype-guided dosing strategy.

While they found that genotype-guided dosing resulted in better outcomes, it was at a relatively high costover $170,000 per quality-adjusted life year gained.

In other analyses, where they took into consideration the limitations of the studies, researchers found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective.

Researchers also looked at the impact of other variables on the cost-effectiveness of genotype-guided dosing.

Eckman says results show that genotype-guided dosing might be worth the costs if it:

  • Is used for patients at high risk for hemorrhage
  • Prevents more than 32 percent of major bleeding events
  • Is available within 24 hours
  • Costs less than $200

"This could be accomplished if testing were done in-house, at lower cost and without delays," he says, noting that currently in most cases these tests need to be sent to outside laboratories which can lead to delays in starting treatment and increased cost. "Furthermore, future studies, such as the recently funded National Institutes of Health COAG trial, need to examine the impact of pharmacogenetic-guided dosing on bleeding risk and monitor outcomes long enough to determine the true duration of benefit."

Eckman also suggests that rather than excluding patients at higher risk for bleeding, studies should offer enrollment if it has already been determined that these patients require warfarin.

"Personalized, predictive medicine offers great promise, but we need to carefully examine the benefits and understand the cost-effectiveness of such strategies before we spend a lot of money on very expensive tests."


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati
Source:Eurekalert

Related biology news :

1. Rethinking the genetic theory of inheritance
2. Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation
3. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
4. New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease
5. Growth of new brain cells requires epigenetic switch
6. Studies examine genetic determinants of ADHD
7. Genetic mutation causes familial susceptibility for degenerative brain disease
8. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
9. Genetic variation may lead to early cardiovascular disease
10. Scientists make strides toward defining genetic signature of Alzheimers disease
11. Safe new therapy for genetic heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):
(Date:7/17/2017)... ... 17, 2017 , ... The Academy of Model Aeronautics (AMA) will host Aviation ... will take place from 9 a.m. to 2 p.m. at the International Aeromodeling Center ... , Aviation Adventure Day will be packed with entertaining activities for the entire family. ...
(Date:7/17/2017)... Ca (PRWEB) , ... July 17, 2017 , ... ... and are characterized by a wide range of overlapping clinical features. The advancement ... discovery in the field of NDD research and testing. , However, designing ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont Pioneer today ... website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists ... breeding, enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is building on ...
(Date:7/15/2017)... ... July 15, 2017 , ... Cuvette manufacturer FireflySci has been making ... the people at FFS have learned that their biggest asset was their amazing customer ... to launch new products to meet the changing needs of scientists at a rapid ...
Breaking Biology Technology: